Geron Corporation - Common Stock

MENLO PARK, Calif., February 2, 2012 - Geron Corporation (Nasdaq: GERN) today announced that the company has completed enrollment in the randomized Phase 2 clinical trial of imetelstat, in combination with paclitaxel, in patients with locally recurrent ...

Amgen Inc., recently decided to acquire Micromet Inc. (NASDAQ:MITI) for the amount of $1.16 billion, faced a drop after announcing lower-than-estimated profit for the fourth quarter because of a decline in its anemia drugs sales while Micromet shares ...

Bears have flocked toward Geron Corporation (GERN - 1.74) today, as approximately 2000 puts have crossed the tape so far, which is seven times above the norm.

A revolution in biotechnology is upon the world. It has been quietly playing out in labs across the world for decades. The paradigm shift in healthcare through regenerative medicine is here.